abstract |
The invention relates to the use of a therapeutic gestagen (for example drospirenon, cyproteron acetate, dienogest) for the production of a medicament for the treatment of Premenstrual Dysphoric Disorders (PMDD), possibly in combination with a natural or synthetic oestrogen (for example estradiol or ethinyl estradiol). |